Table 5.
Outcomes Associated with Coinfection in Hospitalized Patients for COVID-19
| Variable | No Coinfection (N=2064) | Community- Onset CoInfection (N=67) | Unadjusted OR (95% CI) | P Value | Adjusted OR (95% CI) | P Value |
|---|---|---|---|---|---|---|
| Community-onset Coinfection | ||||||
| In-hospital mortalitya | 356 (17.2) | 30 (44.8) | 3.89 (2.39–6.34) |
<.001 | 1.90 (1.06–3.40) |
.03 |
| Discharge to long-term care facility (n=1,745b)a, c | 282 (16.5) | 10 (27.0) | 1.64 (0.78–3.48) |
.19 | 0.69 (0.26–1.82) |
.45 |
| Days of mechanical ventilationd | 0 (0–0) | 0 (0–4) | 3.38 (2.21–5.16) |
<.001 | 3.31 (1.67–6.56) |
.001 |
| Length of staye | 5 (3–9) | 7 (4–11) | 1.27 (1.09–1.48) |
.002 | 1.16 (0.98–1.37) |
.07 |
| Readmission in 60 da (n=1,632b) | 243 (15.2) | 6 (17.1) | 1.15 (0.49–2.71) |
.75 | 0.73 (0.30–1.78) |
.49 |
| 60 day mortalitya | 461 (22.3) | 35 (52.2) | 3.82 (2.32–6.31) |
<.001 | 1.86 (1.05–3.29) |
.03 |
Note. OR, odds ratio; CI, confidence interval.
Mortality, readmission, and discharge to long-term care facilty were adjusted for age, Charlson comorbidity index, admission from nursing home, insurance type, admission to ICU.
Removed those who died in the hospital and without follow up data.
Includes long-term acute-care facility, skilled nursing facility, inpatient rehabilitation, subacute rehabilitation facility.
Days of mechanical ventilation was adusted for age, Charlson comorbidity index, admission from nursing home, admission to ICU.
Length of stay was adjusted for age, gender, Charlson comorbidity index, admission from nursing home, insurance type, admission to ICU.
Hospital-acquired outcomes are additionally adjusted for tocilizumab and steroid use (prior to infection).